External validation and longitudinal extension of the LIPI (lung immune prognostic index) for immunotherapy outcomes in advanced non-small cell lung cancer

被引：0
|
作者：
Barth, D. A. [1 ]
Riedl, J. M. [1 ]
Foris, V. [2 ]
Posch, F. [1 ]
Mollnar, S. [1 ]
Stotz, M. [1 ]
Pichler, M. [1 ,3 ,4 ]
Stoeger, H. [1 ]
Absenger, G. [1 ]
Olschewski, H. [2 ]
Gerger, A. [1 ,5 ]
机构：
[1] Med Univ Graz, Div Clin Oncol, Dept Med, Graz, Austria
[2] Med Univ Graz, Div Pulmonol, Dept Med, Graz, Austria
[3] Med Univ Graz, Res Unit Noncoding RNAs & Genome Editing, Graz, Austria
[4] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA
[5] Ctr Biomarker Res Med, Graz, Austria
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2019年 / 42卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P403
引用
收藏
页码：108 / 108
页数：1
相关论文
共 50 条
  • [1] External validation and longitudinal extension of the LIPI (Lung Immune Prognostic Index) for immunotherapy outcomes in advanced non-small cell lung cancer
    Riedl, J. M.
    Barth, D. A.
    Foris, V.
    Posch, F.
    Mollnar, S.
    Stotz, M.
    Pichler, M.
    Stoeger, H.
    Absenger, G.
    Olschewski, H.
    Gerger, A.
    ANNALS OF ONCOLOGY, 2019, 30
  • [2] The Lung Immune Prognostic Index (LIPI) stratifies prognostic groups in advanced non-small cell lung cancer (NSCLC) patients
    Aldea, Mihaela
    Benitez, Jose Carlos
    Mezquita, Laura
    TRANSLATIONAL LUNG CANCER RESEARCH, 2020, 9 (04) : 967 - 970
  • [3] The Lung Immune Prognostic Index (LIPI), a predictive score for immune checkpoint inhibitors in advanced non-small cell lung cancer (NSCLC) patients
    Mezquita, L.
    Auclin, E.
    Charrier, M.
    Ferrara, R.
    Masip, J. Remon
    Planchard, D.
    Aix, S. Ponce
    Paz-Ares, L.
    Lahmar, J.
    Leroy, L.
    Audigier-Valette, C.
    Cuairan, J. Zeron-Medina
    Lopez, P. Garrido
    Brosseau, S.
    Mazieres, J.
    Caramella, C.
    Adam, J.
    Chaput, N.
    Soria, J-C.
    Besse, B.
    ANNALS OF ONCOLOGY, 2017, 28
  • [4] Association between the lung immune prognostic index (LIPI) and durvalumab consolidation outcomes in patients with locally advanced non-small cell lung cancer (NSCLC)
    Melia, M. Riudavets
    Auclin, E.
    Aboubakar, F.
    Aix, S. Ponce
    Dal Maso, A.
    Bluthgen, V.
    Mielgo, X.
    Mussat, E.
    Reyes, R.
    Benitez, J.
    Lupinacci, L.
    Duchemann, B.
    de Giglio, A.
    Bautista, J.
    Audigier-Valette, C.
    Scheffler, M.
    Campayo, M.
    Besse, B.
    Planchard, D.
    Mezquita, L.
    ANNALS OF ONCOLOGY, 2021, 32 : S1384 - S1384
  • [5] A validation study on the lung immune prognostic index for prognostic value in patients with locally advanced non-small cell lung cancer
    Zhang, Tao
    Xue, Wenji
    Wang, Daquan
    Xu, Kunpeng
    Wu, Linfang
    Wu, Yuqi
    Zhou, Zongmei
    Chen, Dongfu
    Feng, Qinfu
    Liang, Jun
    Xiao, Zefen
    Hui, Zhouguang
    Lv, Jima
    Wang, Xin
    Deng, Lei
    Wang, Wenqing
    Liu, Wenyang
    Wang, Jianyang
    Zhai, Yirui
    Wang, Jie
    Bi, Nan
    Wang, Luhua
    RADIOTHERAPY AND ONCOLOGY, 2021, 156 : 244 - 250
  • [6] Association between lung immune prognostic index, microbiome, and immunotherapy outcomes in non-small cell lung cancer.
    Auclin, Edouard
    Nolin-Lapalme, Alexis
    Richard, Corentin
    Malo, Julie
    Tonneau, Marion
    Benlaifaoui, Myriam
    Ponce, Mayra
    Messaoudene, Meriem
    Okuma, Yusuke
    Hakozaki, Taiki
    Routy, Bertrand
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [7] Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer
    Mezquita, Laura
    Auclin, Edouard
    Ferrara, Roberto
    Charrier, Melinda
    Remon, Jordi
    Planchard, David
    Ponce, Santiago
    Paz Ares, Luis
    Leroy, Laura
    Audigier-Valette, Clarisse
    Felip, Enriqueta
    Zeron-Medina, Jorge
    Garrido, Pilar
    Brosseau, Solenn
    Zalcman, Gerard
    Mazieres, Julien
    Caramela, Caroline
    Lahmar, Jihene
    Adam, Julien
    Chaput, Nathalie
    Soria, Jean Charles
    Besse, Benjamin
    JAMA ONCOLOGY, 2018, 4 (03) : 351 - 357
  • [8] Analysis of the LIPI score as a prognostic factor in advanced non-small cell lung cancer
    Richardet, Eduardo
    Perea, Pablo
    Molina, Matias
    Magi, Ignacio
    Depetris, Santos
    Eduardo Richardet, Martin
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [9] Applicability of lung immune prognostic index (LIPI) to predict efficacy of first-line pembrolizumab in advanced non-small cell lung cancer (NSCLC)
    Mielgo Rubio, X.
    Gomez Rueda, A.
    Antonanzas, M.
    Falagan, S.
    Nunez, J. A.
    Pena, A. M. Sanchez
    Gomez-Barreda, I.
    Martinez Moreno, E.
    Cerezo Gonzalez, S.
    Cabezon Gutierrez, L.
    Sanchez Torres, J. M.
    Jimenez Munarriz, B. E.
    Cervera, R.
    Pangua Mendez, C.
    Calles Blanco, A.
    Lopez Martin, A.
    Lopez Castro, R.
    Sotelo Lezama, M. J.
    Perez Fernandez, E.
    Cruz, P.
    ANNALS OF ONCOLOGY, 2019, 30
  • [10] Lung Immune Prognostic Index in Patients with Non-small Cell Lung Cancer Treated with Either Chemo or Immunotherapy
    Barron, F.
    Mota, B.
    Ramirez Tirado, L. A.
    Zatarain Barron, L.
    Lopez, D.
    Peralta Alvarez, M. P.
    Arrieta, O.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (11) : S1195 - S1195
12345